Statement by DEA Acting Administrator Timothy Shea - Operation Crystal Shield Press Conference - Phoenix,Arizona September 10, 2020

The Drug Enforcement Administration (DEA) Heroin Signature Program (HSP) analyzes hundreds of wholesale-level heroin samples each year to identify the geographic area—Mexico, South America (SA), Southwest Asia (SWA), or Southeast Asia (SEA)—where the samples were manufactured.

The PDIP strives to maintain situational awareness of the threat posed by prescription opioids in Pennsylvania, and to share these analyses with stakeholders in federal, state, and municipal governments. In 2013, the PDIP published a Pharmaceutical Threat Assessment for Pennsylvania that found prescription opioid availability and abuse at epidemic levels...

The Drug Enforcement Administration’s (DEA) Philadelphia Field Division (PFD) Intelligence Program conducted an analysis of drug availability and abuse for the State of Delaware. This product highlights significant findings regarding various drug trends since last reported in 2017. The primary drug threats identified in Delaware are illicit opioids, cocaine, controlled...

The HSP (Heroin Signature Program) is one essential component of the DEA’s Intelligence Program to identify trends in heroin trafficking and distribution in the United States. The objective of the program is to identify and quantify the chemical components of heroin seized at U.S. ports of entry (POE), all non-POE...

Since 2009, Drug Enforcement Administration (DEA) reporting from the Los Angeles Field Division (LAFD) has explored drug-related mortality in the LAFD area of responsibility (AOR), which includes the State of Nevada. In 2019, LAFD personnel reviewed post-mortem toxicology records from the period between 2015 and 2018. These records show that...

DEA's Philadelphia Division conducted a review of laboratory analyzed drug seizures for Pennsylvania. The results of analyzing this data formed the basis for estimating the level of drugs present in Pennsylvania and highlights trends in drug availability.

DEA's revised and updated drug fact sheet about vaping and marijuana concentrates - what are they, what their origin is, what are the common street names for vaping and marijuana concentrates, what do vapes and various concentrates look like, how they are used/abused, what their effect of their use on...

DEA's revised and updated drug fact sheet about the class of drugs known as benzodiazepines (tranquilizers) - what are they, what their origin is, what are the common street names for these drugs, what do they look like, how they are abused, what their effect is on the mind and...

This document is an internal Drug Enforcement Administration quality system document for latent print examination. The effective period of the document is May 4, 2020 to August 18, 2022 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the...